Department of Neurosurgery, Center for interventional diagnosis and treatment, Xuanwu Hospital, Capital Medical University, Beijing, China.
Stroke. 2012 Dec;43(12):3284-90. doi: 10.1161/STROKEAHA.112.662270. Epub 2012 Nov 1.
To investigate the efficacy and safety of percutaneous transluminal angioplasty and stenting (PTAS) for symptomatic middle cerebral artery stenosis compared with standard medical treatment in a low-risk Chinese population.
A prospective, randomized, controlled, single-center clinical trial was conducted comparing PTAS with medical treatment for symptomatic middle cerebral artery stenosis (≥70%). Patients were enrolled according to 1:1 enroll ratio (PTAS: medical). The PTAS group received stenting or balloon angioplasty, whereas the medical treatment group received standard medical treatment (aspirin 100mg plus clopidogrel 75 mg/d), and all the patients were under strict control of the risk factors. The end point events were any kind of ipsilateral stroke or transient ischemic attack, or death from any origin during 1-year follow-up.
The enrollment was stopped after 70 patients were enrolled from August 2007 to December 2010, with a 30-day rate of end point events of 8.3% versus 5.9% (P=0.69) for PTAS and medical group, respectively, and 1-year rate of end point events of 19.4% versus 17.6% (P=0.85), respectively. There was no significant difference in baseline characteristics between the 2 groups. The mean follow-up time, which was ongoing, was 9.9±3.9 and 9.7±4.4 months, respectively. Among the risk factors, hypertension was the independent related to the outcome (P=0.015).
This study showed that endovascular treatment is as safe but not better than medical treatment for symptomatic middle cerebral artery stenosis in a low-risk Chinese population. History of hypertension increases the risk of recurrent ischemic events.
旨在探讨经皮腔内血管成形术和支架置入术(PTAS)治疗低危中国人群症状性大脑中动脉狭窄的疗效和安全性。
采用前瞻性、随机、对照、单中心临床试验,比较了 PTAS 与标准药物治疗(≥70%)对症状性大脑中动脉狭窄的疗效。根据 1:1 入组比例(PTAS:药物)纳入患者。PTAS 组接受支架或球囊血管成形术,而药物治疗组接受标准药物治疗(阿司匹林 100mg 加氯吡格雷 75mg/d),所有患者均严格控制危险因素。终点事件为 1 年随访期间任何同侧卒中或短暂性脑缺血发作,或任何原因死亡。
2007 年 8 月至 2010 年 12 月,共纳入 70 例患者,PTAS 组和药物组的 30 天终点事件发生率分别为 8.3%和 5.9%(P=0.69),1 年终点事件发生率分别为 19.4%和 17.6%(P=0.85)。两组基线特征无显著差异。正在进行的平均随访时间分别为 9.9±3.9 和 9.7±4.4 个月。在危险因素中,高血压是独立相关的(P=0.015)。
本研究表明,对于低危中国人群,血管内治疗与药物治疗在症状性大脑中动脉狭窄的安全性相当,但并不优于药物治疗。高血压病史增加了复发性缺血事件的风险。